within Pharmacolibrary.Drugs.ATC.L;

model L01XG02
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0025166666666666666,
    adminDuration  = 600,
    adminMass      = 27 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.028300000000000002,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.116,
    k12             = 44.5,
    k21             = 44.5
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01XG02</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Carfilzomib is a selective proteasome inhibitor used predominantly in the treatment of multiple myeloma, a type of blood cancer. It is a second-generation irreversible inhibitor of the chymotrypsin-like activity of the 20S proteasome. Carfilzomib is approved for clinical use, particularly in patients with relapsed or refractory multiple myeloma.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters described in adult patients with relapsed and/or refractory multiple myeloma following intravenous administration.</p><h4>References</h4><ol><li><p>Wang, Z, et al., &amp; Infante, JR (2013). Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 41(1) 230–237. DOI:<a href=\"https://doi.org/10.1124/dmd.112.047662\">10.1124/dmd.112.047662</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23118326/\">https://pubmed.ncbi.nlm.nih.gov/23118326</a></p></li><li><p>Yang, J, et al., &amp; Kirk, CJ (2011). Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 39(10) 1873–1882. DOI:<a href=\"https://doi.org/10.1124/dmd.111.039164\">10.1124/dmd.111.039164</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21752943/\">https://pubmed.ncbi.nlm.nih.gov/21752943</a></p></li><li><p>Ou, Y, et al., &amp; Visich, J (2017). Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. <i>Journal of clinical pharmacology</i> 57(5) 663–677. DOI:<a href=\"https://doi.org/10.1002/jcph.850\">10.1002/jcph.850</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27925676/\">https://pubmed.ncbi.nlm.nih.gov/27925676</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01XG02;
